Predictive Oncology Debt to Equity Ratio 2011-2025 | POAI
Current and historical debt to equity ratio values for Predictive Oncology (POAI) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Predictive Oncology debt/equity for the three months ending June 30, 2025 was 0.00.
| Predictive Oncology Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2025-06-30 | $0.01B | $0.00B | -3.08 |
| 2025-03-31 | $0.01B | $0.00B | -41.25 |
| 2024-12-31 | $0.01B | $0.00B | -25.54 |
| 2024-09-30 | $0.01B | $0.00B | 2.81 |
| 2024-06-30 | $0.01B | $0.00B | 1.59 |
| 2024-03-31 | $0.01B | $0.00B | 1.62 |
| 2023-12-31 | $0.01B | $0.01B | 0.74 |
| 2023-09-30 | $0.01B | $0.01B | 0.56 |
| 2023-06-30 | $0.01B | $0.02B | 0.43 |
| 2023-03-31 | $0.01B | $0.02B | 0.35 |
| 2022-12-31 | $0.00B | $0.02B | 0.18 |
| 2022-09-30 | $0.00B | $0.03B | 0.12 |
| 2022-06-30 | $0.00B | $0.03B | 0.09 |
| 2022-03-31 | $0.00B | $0.04B | 0.08 |
| 2021-12-31 | $0.00B | $0.04B | 0.09 |
| 2021-09-30 | $0.00B | $0.05B | 0.07 |
| 2021-06-30 | $0.00B | $0.05B | 0.07 |
| 2021-03-31 | $0.00B | $0.04B | 0.12 |
| 2020-12-31 | $0.01B | $0.00B | 3.94 |
| 2020-09-30 | $0.01B | $0.01B | 1.06 |
| 2020-06-30 | $0.02B | $0.01B | 1.35 |
| 2020-03-31 | $0.02B | $0.01B | 1.42 |
| 2019-12-31 | $0.01B | $0.01B | 0.99 |
| 2019-09-30 | $0.01B | $0.02B | 0.54 |
| 2019-06-30 | $0.01B | $0.02B | 0.45 |
| 2019-03-31 | $0.01B | $0.00B | 71.67 |
| 2018-12-31 | $0.00B | $0.00B | 68.33 |
| 2018-09-30 | $0.00B | $0.00B | 0.79 |
| 2018-06-30 | $0.00B | $0.00B | 0.19 |
| 2018-03-31 | $0.00B | $0.01B | 0.15 |
| 2017-12-31 | $0.00B | $0.00B | 0.35 |
| 2017-09-30 | $0.00B | $0.00B | 0.53 |
| 2017-06-30 | $0.00B | $0.00B | 0.42 |
| 2017-03-31 | $0.00B | $0.00B | 0.37 |
| 2016-12-31 | $0.00B | $0.00B | 2.04 |
| 2016-09-30 | $0.00B | $0.00B | 165.70 |
| 2016-06-30 | $0.00B | $0.00B | 2.69 |
| 2016-03-31 | $0.00B | $0.00B | 0.60 |
| 2015-12-31 | $0.00B | $0.00B | 0.37 |
| 2015-09-30 | $0.00B | $0.01B | 0.45 |
| 2015-06-30 | $0.01B | $-0.01B | -1.12 |
| 2015-03-31 | $0.01B | $-0.01B | -1.13 |
| 2014-12-31 | $0.01B | $-0.01B | -1.16 |
| 2014-09-30 | $0.01B | $0.00B | -1.32 |
| 2014-06-30 | $0.00B | $0.00B | -1.30 |
| 2014-03-31 | $0.00B | $0.00B | -1.60 |
| 2013-12-31 | $0.00B | $0.00B | -1.18 |
| 2013-09-30 | $0.00B | $0.00B | -1.53 |
| 2013-06-30 | $0.00B | $0.00B | -1.13 |
| 2013-03-31 | $0.00B | $0.00B | -1.29 |
| 2012-12-31 | $0.00B | $0.00B | -1.11 |
| 2012-09-30 | $0.00B | $0.00B | -1.20 |
| 2012-06-30 | $0.00B | $0.00B | -1.17 |
| 2012-03-31 | $0.00B | $0.00B | -1.12 |
| 2011-12-31 | $0.00B | $0.00B | -1.17 |
| 2011-09-30 | $0.00B | $0.00B | -1.11 |
| 2011-06-30 | $0.00B | $0.00B | -1.10 |
| 2011-03-31 | $0.00B | $0.00B | -1.22 |
| 2010-12-31 | $0.00B | $0.00B | -1.08 |
| 2010-09-30 | $0.00B | $0.00B | -1.09 |
| 2010-06-30 | $0.00B | $0.00B | -1.10 |
| 2010-03-31 | $0.00B | $0.00B | -1.11 |
| 2009-12-31 | $0.00B | $0.00B | -1.12 |
| 2009-09-30 | $0.00B | $0.00B | -1.18 |
| 2009-06-30 | $0.00B | $0.00B | 0.00 |
| 2009-03-31 | $0.00B | $0.00B | 0.00 |
| 2008-12-31 | $0.00B | 0.00 | |
| 2008-09-30 | $0.00B | $0.00B | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Information Systems | $0.025B | $0.002B |
| Predictive Oncology Inc. is focused on applying artificial intelligence to personalized medicine and drug discovery. Its operating business unit consists of Helomics, TumorGenesis and Skyline Medical. Predictive Oncology Inc., formerly known as Precision Therapeutics Inc., is based in MINNEAPOLIS. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Veeva Systems (VEEV) | United States | $48.476B | 59.15 |
| Tempus AI (TEM) | United States | $12.470B | 0.00 |
| Doximity (DOCS) | United States | $9.841B | 40.73 |
| Hims & Hers Health (HIMS) | United States | $9.345B | 76.02 |
| IRhythm Technologies (IRTC) | United States | $5.680B | 0.00 |
| Hinge Health (HNGE) | United States | $3.475B | 0.00 |
| Privia Health (PRVA) | United States | $2.879B | 180.08 |
| Heartflow (HTFL) | United States | $2.821B | 0.00 |
| Inspire Medical Systems (INSP) | United States | $2.501B | 41.38 |
| 10x Genomics (TXG) | United States | $2.126B | 0.00 |
| Enovis (ENOV) | United States | $1.731B | 9.09 |
| Omnicell (OMCL) | United States | $1.652B | 33.77 |
| Azenta (AZTA) | United States | $1.387B | 60.52 |
| Phreesia (PHR) | United States | $1.355B | 0.00 |
| Schrodinger (SDGR) | United States | $1.346B | 0.00 |
| Clover Health Investments (CLOV) | United States | $1.333B | 0.00 |
| Claritev (CTEV) | United States | $0.953B | 0.00 |
| Fulgent Genetics (FLGT) | United States | $0.840B | 0.00 |
| Evolent Health (EVH) | United States | $0.582B | 0.00 |
| Butterfly Network (BFLY) | United States | $0.561B | 0.00 |
| Talkspace (TALK) | United States | $0.560B | 112.67 |
| Veradigm (MDRX) | United States | $0.517B | 0.00 |
| Standard BioTools (LAB) | United States | $0.450B | 0.00 |
| Carlsmed (CARL) | United States | $0.335B | 0.00 |
| Zepp Health (ZEPP) | Netherlands | $0.325B | 0.00 |
| SOPHiA GENETICS SA (SOPH) | Switzerland | $0.294B | 0.00 |
| TruBridge (TBRG) | United States | $0.286B | 13.15 |
| CapsoVision (CV) | United States | $0.231B | 0.00 |
| Outset Medical (OM) | United States | $0.214B | 0.00 |
| MDxHealth SA (MDXH) | Belgium | $0.210B | 0.00 |
| Health Catalyst (HCAT) | United States | $0.201B | 0.00 |
| Insight Molecular Diagnostics (IMDX) | United States | $0.195B | 0.00 |
| Nyxoah SA (NYXH) | Belgium | $0.183B | 0.00 |
| KORU Medical Systems (KRMD) | United States | $0.181B | 0.00 |
| CareCloud (CCLD) | United States | $0.143B | 7.84 |
| EUDA Health Holdings (EUDA) | Singapore | $0.113B | 0.00 |
| Pulmonx (LUNG) | United States | $0.079B | 0.00 |
| NetraMark Holdings (AINMF) | Canada | $0.075B | 0.00 |
| American Well (AMWL) | United States | $0.065B | 0.00 |
| HeartBeam (BEAT) | United States | $0.058B | 0.00 |
| P3 Health Partners (PIII) | United States | $0.054B | 0.00 |
| Evaxion - (EVAX) | Denmark | $0.040B | 0.00 |
| 111 (YI) | China | $0.036B | 0.00 |
| Precipio (PRPO) | United States | $0.033B | 0.00 |
| Lunai Bioworks (LNAI) | United States | $0.021B | 0.00 |
| Zhongchao (ZCMD) | China | $0.017B | 0.00 |
| Healthcare Triangle (HCTI) | United States | $0.016B | 0.00 |
| Bullfrog AI Holdings (BFRG) | United States | $0.011B | 0.00 |
| Movano (MOVE) | United States | $0.010B | 0.00 |
| Strata Skin Sciences (SSKN) | United States | $0.009B | 0.00 |
| PROFUSA (PFSA) | United States | $0.008B | 0.00 |
| HeartSciences (HSCS) | United States | $0.007B | 0.00 |
| Tivic Health Systems (TIVC) | United States | $0.002B | 0.00 |
| Mobile-health Network Solutions (MNDR) | Singapore | $0.002B | 0.00 |
| MSP Recovery (MSPR) | United States | $0.000B | 0.00 |